ANZMIG aims to:

Foster and advance education and training in the pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prevention of fungal infections.

Develop national guidelines for management of mycological infections.

Facilitate and promote investigator-initiated, collaborative clinical and applied mycological research throughout Australia and New Zealand.

Contribute to program development of other ad hoc educational meetings involving Mycology.

ANZMIG educational activities include:

Organising the Mycology Masterclass Program every two years

Inviting Advanced Trainees in Infectious Diseases/Microbiology to present their work at three ANZMIG Educational meetings each year.

An ANZMIG Symposia at the ASID Annual Scientific Meeting.

ANZMIG- Asia fungal Working Group (ISHAM) webinars every 3 months

Contributions to ASID INTREPID webinars.

ANZMIG awards a seed grant to an ASID member valued at $20,000 every two years to support a collaborative research project led by an early career researcher.

Committee:

Co-Chairs: A/Prof Sarah Kidd and Dr Abby Douglas
Immediate past Co-Chair: Prof Caitlin Keighley
Secretary: Prof Sharon Chen
Past Secretary: A/Prof Sarah Kidd
Scientific Chair: Dr Natalie Davidson
Trainee Representative: Dr Annalise Unsworth
Clinical WG Lead: A/Prof Justin Beardsley
Laboratory WG Lead: Prof Catriona Halliday

Mycology Online
ISHAM
Fungal MLST Database
ISHAM Barcoding Database

• Mycological testing in Australasian clinical mycology laboratories: survey of the current state and access to testing. Pathology. Apr 2026; 58(3):341-346.
  

• Current Epidemiology and Infection Characteristics of Non-Aspergillus Mold Infections: A Multicenter Study in Australia and New Zealand. Clinical Infectious Diseases 21 Jan 2026:ciag029. 
  

• Management, Outcomes, and Predictors of Mortality of Cryptococcus Infection in Patients Without HIV: A Multicenter Study in 46 Hospitals in Australia and New Zealand. Clinical Infectious Diseases. 30 Apr 2025; 80(4):817-825.
  

• Landscape analysis of commercially available and pipeline in vitro diagnostics for fungal priority pathogens. Geneva: World Health Organization; 2025.
  

• Antifungal agents in clinical and preclinical development: overview and analysis. Geneva: World Health Organization; 2025.
  

• Informing the World Health Organization Fungal Priority Pathogens List (WHO-FPPL): A collection of systematic reviews. Medical Mycology 27 Jun 2024;62(6):myae046
  

• Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list Medical Mycology 27 Jun 2024;62(6):myae039
  

• Candida tropicalis—A systematic review to inform the World Health Organization of a fungal priority pathogens list Medical Mycology 27 Jun 2024;62(6):myae040
  

• Pichia kudriavzevii (Candida krusei): A systematic review to inform the World Health Organisation priority list of fungal pathogens. Medical Mycology 27 Jun 2024;62(6):myad132
  

• Candida auris—a systematic review to inform the world health organization fungal priority pathogens list. Medical Mycology 27 Jun 2024;62(6):myae042
  

• Cryptococcosis—a systematic review to inform the World Health Organization Fungal Priority Pathogens List. Medical Mycology 27 June 2024;62(6):myae043
  

• Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list. Medical Mycology 27 Jun 2024;62(6):myad131
  

• Candida glabrata (Nakaseomyces glabrata): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal Priority Pathogens List. Medical Mycology 27 Jun 2024;62(6):myae041
  

• Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list. Medical Mycology 27 Jun 2024;62(6):myae038
  

• Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens. Medical Mycology 27 Jun 2024;62(6):myae044
  

• Aspergillus fumigatus—a systematic review to inform the World Health Organization priority list of fungal pathogens. Medical Mycology 27 Jun 2024;62(6):myad129
  

• Mucorales: A systematic review to inform the World Health Organization priority list of fungal pathogens. Medical Mycology 27 Jun 2024;62(6):myad130
  

• Candida albicans—A systematic review to inform the World Health Organization Fungal Priority Pathogens List. Medical Mycology 27 Jun 2024;62(6):myae045
  

• Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens. Tina Marinelli, Medical Mycology 27 Jun 024;62(6):myad128
  

• Talaromyces marneffei, Coccidioides species, and Paracoccidioides species—a systematic review to inform the World Health Organization priority list of fungal pathogens. Medical Mycology 27 Jun 024;62(6):myad133
  

• Time-to-positivity in bloodstream infection for Candida species as a prognostic marker for mortality. Medical Mycology. 3 Apr 2023; 1(4):myad028.
  

• Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections. Clinical Microbiology Reviews. 13 Jun 2024; 37(2):e0000423.
  

• Invasive aspergillosis in adult patients in Australia and New Zealand: 2017-2020. Lancet Reg Health West Pac. 4 Sept 2023; 40:100888.
  

• Current Epidemiology and Clinical Features of Cryptococcus Infection in Patients Without Human Immunodeficiency Virus: A Multicenter Study in 46 Hospitals in Australia and New Zealand. Clinical Infectious Diseases. 26 May 2023.
  

• Introduction to the updated Australasian consensus guidelines  for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021. Internal Medicine Journal 51(S7):3-17.
  

• Consensus guidelines for antifungal stewardship , surveillance and infection prevention, 2021. Internal Medicine Journal 51(S7):18-36
  

• Consensus guidelines for optimising antifungal drug delivery  and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. Internal Medicine Journal 51(S7):37-66
  

• Consensus guidelines for antifungal prophylaxis  in haematological malignancy and haemopoietic stem cell transplantation, 2021. Internal Medicine Journal 51(S7):67-88
  

• Consensus guidelines for the diagnosis and management  of invasive candidiasis in haematology, oncology and intensive care settings, 2021. Internal Medicine Journal 51(S7):89-117
  

• Consensus guidelines for the diagnosis and management  of cryptococcosis and rare yeast infections in the haematology/oncology setting, 2021. Internal Medicine Journal 51(S7):118-142
  

• Consensus guidelines for the diagnosis and management  of invasive aspergillosis, 2021. Internal Medicine Journal 51(S7):143-176
  

• Consensus guidelines for the diagnosis and management  of invasive fungal disease due to moulds other than Aspergillus in the haematology/oncology setting, 2021. Internal Medicine Journal 51(S7):177-219
  

• Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021. Internal Medicine Journal 51(S7):220-233
  

• Diagnosis, management and prevention of Candida auris in hospitals.Ong CW, Chen SC, Clark JE, Halliday CL, Kidd SE, Marriott DJ, Marshall CL, Morris AJ, Morrissey CO, Roy R, Slavin MA, Stewardson AJ, Worth LJ, Heath CH; Australian and New Zealand Mycoses Interest Group (ANZMIG); and the Healthcare Infection Control Special Interest Group (HICSIG). Intern Med J. 2019 Oct;49(10):1229-1243. doi: 10.1111/imj.14612. (Please note, statement now deprecated)
  

• ANZMIG Publications 2005-2017: See list.